BioInsights - Manufacturing of NK cells for the clinic: the Spanish experience
Sep
27
2022
On demand

Manufacturing of NK cells for the clinic: the Spanish experience

Sponsor
Manufacturing of NK cells for the clinic: the Spanish experience

In this webinar Dr. Antonio Perez-Martinez will discuss a standardized method to manufacture a high number of clinical-grade NK cells, ideal for infusing into patients. The talk will further expand on the optimization of protocols and a glimpse into the clinical data results of infused NK cells.

  • How to design your cell manufacturing 
  • How to ensure compliance and quality in your cell product 
  • The impact of the starting material on the final product

Antonio Perez-Martinez, PhD

Head of Pediatric Hemato-Oncology and Hematopoietic Transplant Service, La Paz University Hospital, Madrid

Dr. Antonio Perez-Martinez, MD, PhD, is a Medical Specialist in Pediatrics and the Head of Pediatric Hematology and Oncology Service at the University Hospital La Paz, Madrid, Spain. He is also the Head of the Pediatric Department at the Autonomous University of Madrid, Spain, and the Principle Investigator at the Foundation for Biomedical Research, Hospital La Paz, and has experience as the Principal Investigator of over 20 active research projects.

Marty Giedlin, PhD

Senior Vice President, Head, Technical Operations, Senti Bio

Dr. Giedlin is currently the VP, Head of Tech Ops at Senti BioSciences supporting the allogeneic NK-CAR programs. Before his joining Senti, he led the PD groups at PACT Pharma (non-viral process for generating autologous neoTcR+ T cells), Poseida (non-viral process for generating autologous CAR-T’s), and Novartis (clinical and commercial manufacturing process for Kymriah). His experience covers over 25 years of various approaches to harness the immune response to treat cancer and infectious disease, starting with Proleukin rIL-2 (aldesleukin; Chiron), Oncolytic adenovirus (Onyx), Listeria-based cancer vaccines (Cerus), and CCR5 knockout CD4+ T cells for HIV+ patients (Sangamo). In addition, he led the implementation of AAV clinical manufacturing to support the Hemophilia, LSD, and neurodegenerative disease programs.

Mariam L. Ammari, MS

Senior Project Director, Clinical Cell Engineering, MD Anderson Cancer Center

A Passionate scientist about cancer research and immunology. 10 years of extensive experience in cutting-edge and novel cell therapy technologies such as CRISPR-based Gene-editing, CAR T-cells, CAR-NK cells, and several other GMP protocols, including expansion and cryopreservation of feeder cells. Proficient in a wide range of highly specialized aseptic cell manipulation techniques, cell culture, and development of new procedures.

SPEAKERS

Antonio Perez-Martinez
Antonio Perez-Martinez
Head of Pediatric Hemato-Oncology and Hematopoietic Transplant Service, La Paz University Hospital, Madrid
Marty Giedlin, PhD
Marty Giedlin, PhD
Senior Vice President, Head Technical Operations, Senti Bio
Mariam Ammari, MS
Mariam Ammari, MS
Clinical Cell Therapy Specialist, MD Anderson Cancer Center

You might also like